Woojung Bio issues 35 billion won CB, changes largest shareholder to Kolmar Holdings… Sales continue to grow
Issued 35 billion won 9th convertible bonds to Kolmar Holdings in March 2026 (conversion price 2,325 won, maturity 2030)
Largest shareholder changed: Cheon Byung-nyeon → Cheon Hee-jung (inheritance), then voting rights of 33.18% from 3 shareholders entrusted to Kolmar Holdings
Quarterly sales 11.03 billion won (up 32.7% from previous quarter), net loss 0.21 billion won (improved from 2.08 billion loss)
Debt ratio 417.4% (up from 254.9% at year-end), capital surplus 48.61 billion won, retained earnings deficit -31.27 billion won